Based on the aforementioned reasons, there is a significant difference in PBMCs between COVID-19 patients and non-COVID-19 patients regarding NCS1 and its related genes (Figure 6C), indicating that NCS1 could serve as a potential therapeutic target for COVID-19, and the development of an NCS1 mRNA vaccine is plausible. This evidence concerns the gene NCS1 and COVID-19.